Scynexis names new CEO
This article was originally published in Scrip
Executive Summary
Drug discovery and development company Scynexis has appointed Dr Marco Taglietti CEO, effective from 1 April 2015. Dr Taglietti, a member of Scynexis' board of directors, will succeed Dr Yves Ribeill in the position. Dr Ribeill will remain the company's president and will continue to serve on the company's board. In an unrelated matter Scynexis said Dr Carole Sable, the company's current chief medical officer, is stepping down effective 20 February 2015.